SauliusKazimierasGirniusMD

Physician

Dr. Girnius is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
10506A Montgomery Rd
Montgomery, OH 45242
Phone+1 513-853-1300

Fax+1 513-451-4118

PubMed

1 citations
-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Robert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, Suman Kambhampati, Joshua Richter
Future Oncology. 2024-01-01
2 citations
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati
Blood Cancer Journal. 2023-09-19
11 citations
Bleeding and thrombotic risk in pregnant women with Fontan physiology
Andrea Girnius, Dominica Zentner, Anne Marie Valente, Petronella G. Pieper, Katherine E. Economy
Heart. 2021-09-01

Abstracts/Posters

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
Saulius K. Girnius, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genomic Landscape of Sex Disparities in Multiple Myeloma
Saulius K. Girnius, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation
Saulius K. Girnius, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019